Effects of Cerebrolysin on the Neurodevelopmental Outcomes in Infants with Down Syndrome: A Randomized Controlled Pilot Trial

References

• Alam El-Deen, N., Alwakeel, A. A., El-Gilany, A. H., & Wahba, Y. (2021). Burden of family caregivers of Down syndrome children: A cross-sectional study. Family Practice, 38(2), 160–165. https://doi.org/10.1093/fampra/cmaa097
   PubMed Web of Science ®Google Scholar
• Alvarez, X. A., Cacabelos, R., Sampedro, C., Aleixandre, M., Linares, C., Granizo, E., Doppler, E., & Moessler, H. (2011). Efficacy and safety of Cerebrolysin in moderate to moderately severe Alzheimer’s disease: Results of a randomized, double-blind, controlled trial investigating three dosages of Cerebrolysin. European Journal of Neurology, 18(1), 59–68. https://doi.org/10.1111/j.1468-1331.2010.03092.x
   PubMed Web of Science ®Google Scholar
• Álvarez, X. A., Figueroa, J., & Muresanu, D. (2013). Peptidergic drugs for the treatment of traumatic brain injury. Future Neurology, 8(2), 175–192. https://doi.org/10.2217/fnl.12.95
   Google Scholar
• Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020). Down syndrome. Nature Reviews Disease Primers, 6(1), 9. doi:10.1038/s41572-019-0143-7
   PubMed Web of Science ®Google Scholar
• Ashrafi, M. R., Mohammadi, M., Vafaee-Shahi, M., Tavasoli, A. R., Badv, R. S., Shariat, N., Hashemii, M., Shahrokhi, A., Shojaaldini, H., Tahernia, L., & Alizadeh Chamkhaleh, M. (2019). A clinical trial evaluating the safety and efficacy of cerebrolysin in children with autism spectrum disorders. Iranian Journal of Pediatrics, 29(6), e80991. https://doi.org/10.5812/ijp.80991
   Web of Science ®Google Scholar
• Bayley, N. (2006). Bayley scales of infant and toddler development®3rd edition (Bayley-III®): Technical manual. Harcourt assessment, Psych. Corporation.
   Google Scholar
• Broglio, K. (2018). Randomization in clinical trials: Permuted blocks and stratification. Jama, 319(21), 2223–2224. https://doi.org/10.1001/jama.2018.6360
   PubMed Web of Science ®Google Scholar
• Carvalho, R. L., & Vasconcelos, D. A. (2011). Motor behavior in Down syndrome: Atypical sensoriomotor control. In S. Dey (Ed.), Prenatal Diagnosis and Screening for Down Syndrome (pp. 33–42). InTech Publisher.
   Google Scholar
• Chen, N., Yang, M., Guo, J., Zhou, M., Zhu, C., & He, L. (2013). Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews, (1), CD008900. doi:10.1002/14651858.CD008900.pub2
   PubMed Web of Science ®Google Scholar
• Chutko, L. S., Yakovenko, E. A., Surushkina, S. Y., Kryukova, E. M., & Palaieva, S. V. (2017). Éffektivnost’ tserebrolizina pri rasstroĭstvakh autisticheskogo spektra [The efficacy of cerebrolysin in the treatment of autism spectrum disorders]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 117(9), 71–75. https://doi.org/10.17116/jnevro20171179171-75
   PubMedGoogle Scholar
• Chutko, L. S., Surushkina, S. Y., Yakovenko, E. A., Anisimova, T. I., Volov, M. B., Rozhkova, A. V., & Sergeev, A. V. (2018). Komorbidnye kognitivnye narusheniia u deteĭ s nochnym énurezom i ikh lechenie [Comorbid cognitive impairments in children with nocturnal enuresis and their treatment]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 118(5–2), 57–63. https://doi.org/10.17116/jnevro20181185257
   PubMedGoogle Scholar
• Costa, A. C. S. (2011). On the promise of pharmacotherapies targeted at cognitive and neurodegenerative components of Down syndrome. Developmental Neuroscience, 33(5), 414–427. https://doi.org/10.1159/000330861
   PubMed Web of Science ®Google Scholar
• Costa, A. C. S., & Scott-McKean, J. J. (2013). Prospects for improving brain function in individuals with Down syndrome. CNS Drugs, 27(9), 679–702. https://doi.org/10.1007/s40263-013-0089-3
   PubMed Web of Science ®Google Scholar
• Cui, S., Chen, N., Yang, M., Guo, J., Zhou, M., Zhu, C., & He, L. (2019). Cerebrolysin for vascular dementia. Cochrane Database of Systematic Reviews, (11), CD008900. https://doi.org/10.1002/14651858.CD008900.pub3
   Google Scholar
• De Graaf, G., Buckley, F., & Skotko, B. G. (2017). Estimation of the number of people with Down syndrome in the United States. Genetics in Medicine, 19(4), 439–447. https://doi.org/10.1038/gim.2016.127
   PubMed Web of Science ®Google Scholar
• El-Gilany, A., El-Wehady, A., & El-Wasify, M. (2012). Updating and validation of the socioeconomic status scale for health research in Egypt. Eastern Mediterranean Health Journal, 18(9), 962–968. https://doi.org/10.26719/2012.18.9.962
   PubMedGoogle Scholar
• Fan, F., Liu, H., Shi, X., Ai, Y., Liu, Q., & Cheng, Y. (2022). The efficacy and safety of Alzheimer’s disease therapies: An updated umbrella review. Journal of Alzheimer’s Disease, 85(3), 1195–1204. https://doi.org/10.3233/JAD-215423
   PubMed Web of Science ®Google Scholar
• Forrest, M. P., Parnell, E., & Penzes, P. (2018). Dendritic structural plasticity and neuropsychiatric disease. Nature Reviews. Neuroscience, 19(4), 215–234. https://doi.org/10.1038/nrn.2018.16
   PubMed Web of Science ®Google Scholar
• Fragoso, Y. D., & Dantas, D. C. (2002). Cerebrolysin for Alzheimer’s disease. Cochrane Database of Systematic Reviews, (3), CD003081. https://doi.org/10.1002/14651858.CD003801
   Google Scholar
• Ghaffarpasand, F., Torabi, S., Rasti, A., Niakan, M. H., Aghabaklou, S., Pakzad, F., Beheshtian, M. S., & Tabrizi, R. (2019). Effects of cerebrolysin on functional outcome of patients with traumatic brain injury: A systematic review and meta-analysis. Neuropsychiatric Disease and Treatment, 15, 127–135. https://doi.org/10.2147/NDT.S186865
   PubMed Web of Science ®Google Scholar
• Gorbachevskaya, N., Bashina, V., Gratchev, V., & Iznak, A. (2001). Cerebrolysin therapy in Rett syndrome: Clinical and EEG mapping study. Brain & Development, 23(Suppl. 1), 90–93. https://doi.org/10.1016/S0387-7604(01)00349-7
   Google Scholar
• Grieco, J., Pulsifer, M., Seligsohn, K., Skotko, B., & Schwartz, A. (2015). Down syndrome: Cognitive and behavioral functioning across the lifespan. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 169(2), 135–149. https://doi.org/10.1002/ajmg.c.31439
   PubMed Web of Science ®Google Scholar
• Hassanein, S. M. A., Deifalla, S. M., El-Houssinie, M., & Mokbel, S. A. (2016). Safety and efficacy of cerebrolysin in infants with communication defects due to severe perinatal brain insult: A randomized controlled clinical trial. Journal of Clinical Neurology, 12(1), 79–84. https://doi.org/10.3988/jcn.2016.12.1.79
   PubMed Web of Science ®Google Scholar
• Heiss, W.-D., Brainin, M., Bornstein, N. M., Tuomilehto, J., & Hong, Z. (2012). Cerebrolysin in patients with acute ischemic stroke in Asia: Results of a double-blind, placebo-controlled randomized trial. Stroke, 43(3), 630–636. https://doi.org/10.1161/STROKEAHA.111.628537
   PubMed Web of Science ®Google Scholar
• Krasnoperova, M. G., Bashina, V. M., Skvortsov, I. A., & Simashkova, N. V. (2003). Vliianie tserebrolizina na kognitivnye funktsii pri detskom autizme i sindrome Aspergera [The effect of cerebrolysin on cognitive functions in childhood autism and in Asperger syndrome]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova Article in Russian , 103(6), 15–18. https://pubmed.ncbi.nlm.nih.gov/12872620/
   PubMedGoogle Scholar
• Liogier d’Ardhuy, X., Edgin, J. O., Bouis, C., de Sola, S., Goeldner, C., Kishnani, P., Nöldeke, J., Rice, S., Sacco, S., Squassante, L., Spiridigliozzi, G., Visootsak, J., Heller, J., & Khwaja, O. (2015). Assessment of cognitive scales to examine memory, executive function and language in individuals with Down syndrome: Implications of a 6-month observational study. Frontiers in Behavioral Neuroscience, 9, 300. https://doi.org/10.3389/fnbeh.2015.00300
   PubMed Web of Science ®Google Scholar
• Ma, J. Q., Zhou, L. L., Hu, Y. Q., Liu, J. R., Liu, S. S., Zhang, J., & Sheng, X. Y. (2012). A summary index of infant and child feeding practices is associated with child growth in urban Shanghai. BMC Public Health, 12(1), 568. https://doi.org/10.1186/1471-2458-12-568
   PubMedGoogle Scholar
• Malak, R., Kotwicka, M., Krawczyk-Wasielewska, A., Mojs, E., & Szamborski, W. (2013). Motor skills, cognitive development and balance functions of children with Down syndrome. Annals of Agricultural and Environmental Medicine, 20(4), 803–806. https://pubmed.ncbi.nlm.nih.gov/24364457/
   PubMed Web of Science ®Google Scholar
• Masliah, E., & Diez-Tejedor, E. (2012). The pharmacology of neurotrophic treatment with Cerebrolysin: Brain protection and repair to counteract pathologies of acute and chronic neurological disorders. Drugs of Today (Barcelona, Spain: 1998), 48(Suppl. A), 3–24. https://doi.org/10.1358/dot.2012.48(Suppl.A).1739716
   PubMedGoogle Scholar
• McCarney, R., Warner, J., Iliffe, S., Van Haselen, R., Griffin, M., & Fisher, P. (2007). The Hawthorne effect: A randomised, controlled trial. BMC Medical Research Methodology, 7(1), 30. https://doi.org/10.1186/1471-2288-7-30
   PubMed Web of Science ®Google Scholar
• Nasiri, J., & Safavifar, F. (2017). Effect of cerebrolysin on gross motor function of children with cerebral palsy: A clinical trial. Acta Neurologica Belgica, 117(2), 501–505. https://doi.org/10.1007/s13760-016-0743-x
   PubMed Web of Science ®Google Scholar
• Nelson, P. G., McCune, S. K., Ades, A. M., & Nelson, K. B. (2001). Glial-neurotrophic mechanisms in Down syndrome. Journal of Neural Transmission. Supplementum, 61, 85–94. https://doi.org/10.1007/978-3-7091-6262-0_7
   Google Scholar
• Onose, G., Daia-Chendreanu, C., Haras, M., Ciurea, A. V., & Anghelescu, A. (2011). Traumatic brain injury: Current endeavours and trends for neuroprotection and related recovery. Romanian Neurosurgery, 18(1), 11–30. https://www.journals.lapub.co.uk/index.php/roneurosurgery/article/view/535
   Google Scholar
• Petrukhin, A. S., & Pylaeva, O. A. (2014). Церебролизин в педиатрической неврологической практике [Cerebrolysin in pediatric neurology practice]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova [Article in Russian] , 114(1–2), 75–80. https://pubmed.ncbi.nlm.nih.gov/24637827/
   PubMedGoogle Scholar
• Quach, T. T., Stratton, H. J., Khanna, R., Kolattukudy, P. E., Honnorat, J., Meyer, K., & Duchemin, A. M. (2021). Intellectual disability: Dendritic anomalies and emerging genetic perspectives. Acta Neuropathologica, 141(2), 139–158. https://doi.org/10.1007/s00401-020-02244-5
   PubMed Web of Science ®Google Scholar
• Roizen, N. J., & Patterson, D. (2003). Down’s syndrome. The Lancet, 361(9365), 1281–1289. https://doi.org/10.1016/S0140-6736(03)12987-X
   PubMed Web of Science ®Google Scholar
• Rojnueangnit, K., Khaosamlee, P., Chunsuwan, I., Vorravanpreecha, N., Lertboonnum, T., Rodjanadit, R., & Sriplienchan, P. (2020). Quality of life and comprehensive health supervision for children with Down syndrome in Thailand. Journal of Community Genetics, 11(3), 351–358. https://doi.org/10.1007/s12687-020-00458-4
   PubMed Web of Science ®Google Scholar
• Strilciuc, S., Vécsei, L., Boering, D., Pražnikar, A., Kaut, O., Riederer, P., & Battistin, L. (2021). Safety of cerebrolysin for neurorecovery after acute ischemic stroke: A systematic review and meta-analysis of twelve randomized-controlled trials. Pharmaceuticals (Basel, Switzerland), 14(12), 1297. https://doi.org/10.3390/ph14121297
   PubMedGoogle Scholar
• Thome, J., & Doppler, E. (2012). Safety profile of Cerebrolysin: Clinical experience from dementia and stroke trials. Drugs of Today (Barcelona, Spain: 1998), 48(Suppl. A), 63–69. https://pubmed.ncbi.nlm.nih.gov/22514795/
   PubMedGoogle Scholar
• Vester, J. C., Buzoianu, A. D., Florian, S. I., Hömberg, V., Kim, S. H., Lee, T., Matula, C., Poon, W. S., Sandesc, D., von Steinbüchel, N., Strilciuc, S., Vos, P. E., von Wild, K., & Muresanu, D. (2021). Cerebrolysin after moderate to severe traumatic brain injury: Prospective meta-analysis of the CAPTAIN trial series. Neurological Sciences, 42(11), 4531–4541. https://doi.org/10.1007/s10072-020-04974-6
   PubMed Web of Science ®Google Scholar
• Wajuihian, S. O. (2016). Down syndrome: An overview. African Vision and Eye Health, 75(1), a346. https://doi.org/10.4102/aveh.v75i1.346
   Google Scholar
• Watt, N., Wetherby, A., & Shumway, S. (2006). Prelinguistic predictors of language outcome at 3 years of age. Journal of Speech, Language, and Hearing Research, 49(6), 1224–1237. https://doi.org/10.1044/1092-4388(2006/088)
   PubMed Web of Science ®Google Scholar